NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a biotechnology firm focusing on cancer immunotherapies and targeted drug conjugates, with a current market capitalization of $37 million, has provided a ...

Patients taking a commonly used stimulant for the treatment of binge eating disorder experienced mixed results, according to ...

A team of researchers from the National University of Singapore (NUS) has developed a novel method to enhance the precision ...